Out of Stock
Compounded semaglutide is a weekly shot that uses the same active ingredient as Ozempic® and Wegovy® .
You can lose 20% or more of your weight with Semaglutide.
Out of Stock
Full Description
Rybelsus is an FDA-approved prescription medication for adults with type 2 diabetes mellitus. As the first oral GLP-1 receptor agonist, it mimics natural hormones to stimulate insulin release, regulate glucose levels, and slow digestion—helping to manage blood sugar effectively.
Clinical studies have shown that patients on the highest dose (14 mg) experienced improved blood sugar control and an average weight loss of 4.4 kg over 52 weeks.
Rybelsus is intended to be used alongside diet and exercise to improve glycemic control in patients with type 2 diabetes.
In this plan
Features
Directions
Learn More (Clinical studies)
Compounded semaglutide is a weekly shot that uses the same active ingredient as Ozempic® and Wegovy® .
You can lose 20% or more of your weight with Semaglutide.
We work with registered, certified third-party labs that run extensive,thorough quality checks on every Semaglutide medication. We test four criteria to ensure absolute quality and safety.
Endotoxicity
Passed
pH Test
Passed
Sterility Test
Passed
Potency Test
Passed
Select your medication.
Pick the treatment plan you want. Our Doctors recommend the longer plans for new users and best results.
Speak to a Doctor via online video consultation.
Receive medication.
Ongoing care and support.
Meet our expert. Dr Ben Ng.
Singapore’s leading Endocrinologist Specialist and OVA programme advisor.
Doctor Consultation
GLP-1 Prescription
Nutritional Support Guide
Ongoing Care and Support
Services
Weight ManagementDISCLAIMER: Ova is a digital health platform which facilities the provision of healthcare services by connecting its users with licensed doctors, pharmacies and other licensed healthcare institutions. Ova itself is neither a licensed clinic nor a licensed pharmacy. Ova does not prescribe, store or dispense any medication. For further information, refer to our terms of use.
© Ova 2025. All Rights Reserved.